India: Carlyle Group’s generic pharma platform Viyash, invests in Appcure Labs and Appco Pharma LLC

IFLR is part of Legal Benchmarking Limited, 1-2 Paris Garden, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement


India: Carlyle Group’s generic pharma platform Viyash, invests in Appcure Labs and Appco Pharma LLC

Sponsored by

22LuthraAndLuthra.png

L&L Partners Law Offices advised the Carlyle Group on the acquisition of 100% stake of Appcure Labs Private Limited and the acquisition of majority stake in Appco Pharma LLC through its generic pharma platform, Viyash Life Sciences Private Limited.

Transaction: L&L Partners Law Offices advised the Carlyle Group on the acquisition of 100% stake of Appcure Labs Private Limited and the acquisition of majority stake in Appco Pharma LLC through its generic pharma platform, Viyash Life Sciences Private Limited.

Our role: The Firm advised the client in relation to all stages of the acquisition of Appcure, including of structuring the transaction, advising on various regulatory issues, conducting legal due diligence, drafting and finalising definitive documents, and pre-closing and closing formalities. The Firm also advised the client on various issues under Indian law with respect to its acquisition of Appco Pharma LLC, including transaction structure and regulatory issues relating to overseas direct investment.

Ropes and Gray was the US counsel to Carlyle Group/ Viyash for the acquisition of Appco Pharma LLC.

The Team

The transaction team from L&L was led by Partner, Anshuman Mozumdar and consisted of Associates, Ankur Kumar and Aditi Halder.


The due diligence team was led by Partner, Anshuman Mozumdar, and consisted of Associates, Ankur Kumar, Aditi Halder, Anirudh Gotety and Sakshi Saraogi.

Gift this article